DEF 14A: Fulgent Genetics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Fulgent Genetics announces its 2024 Annual Meeting of Stockholders to be held on May 16, 2024, focusing on director elections, auditor ratification, and executive compensation approval.

Summary

• Fulgent Genetics will hold its 2024 Annual Meeting of Stockholders on May 16, 2024, at its El Monte, California offices.
• Stockholders will vote on the election of four directors, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
• The board of directors recommends voting in favor of all three proposals.
• The record date for determining stockholders eligible to vote is March 21, 2024.
• Proxy materials are being made available online, with instructions provided to stockholders on how to access the materials and vote.
• The company highlights its 2023 core revenue growth of 44% year-over-year and a compound annual growth of 68% from 2021 to 2023.
• Fulgent Genetics ended 2023 with $848 million in cash, cash equivalents, and marketable securities.
• The company is progressing with its Fulgent Pharma pipeline, aiming for an Investigational New Drug application for FID-022 by the end of 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While core business metrics show positive growth, overall revenue is down significantly. The company's strong cash position and pipeline progress are encouraging, but the decline in total revenue and negative EBITDA temper the outlook.

Positives

• Strong core revenue growth of 44% year-over-year in 2023 indicates a healthy underlying business.
• A substantial cash balance of $848 million provides financial flexibility for future investments and operations.
• Progress in the Fulgent Pharma pipeline, with plans for an Investigational New Drug application, suggests potential future revenue streams.
• The board is actively engaged in ESG matters, demonstrating a commitment to sustainability and corporate responsibility.
• The company has implemented a formal Supplier Code of Conduct and Modern Slavery Statement.

Negatives

• Total revenue decreased by 53% year-over-year in 2023, primarily due to the decline in COVID-19 testing revenue.
• The company experienced a total revenue compound annual loss of 46% from 2021 to 2023.
• Core EBITDA was negative in 2023, at $(9.2) million.

Risks

• The company's future performance is subject to risks described in its Annual Report on Form 10-K.
• Reliance on forward-looking statements, which are not guarantees of performance.
• Potential risks associated with the Fulgent Pharma pipeline and the success of its drug candidates.
• Cybersecurity risks and the need to protect data privacy and information security.
• The company faces business, operational, strategic, research and development, financial, legal and regulatory risks.

Future Outlook

The company is focused on progressing its Fulgent Pharma pipeline, with a goal to file an Investigational New Drug application for FID-022 by the end of 2024. The company aims to improve pharmacokinetic profile, as well as safety and efficacy.

Industry Context

The company operates in the healthcare, diagnostics, and research sectors, competing with companies of comparable market capitalization and revenue size. The peer group includes companies like Biodesix, CareDx, Castle Biosciences, GeneDx Holdings Corp., Guardant Health, Invitae, Myriad Genetics, NanoString Technologies, NeoGenomics, Opko Health, Pacific Biosciences, and Veracyte.

Comparison to Industry Standards

• The company benchmarks its executive compensation against a peer group of 12 healthcare and diagnostics and research companies.
• Peer organizations are located within a multi-state geographic region and are of comparable market capitalization and revenue size to the Company.
• The companies included in the peer group have market capitalization or revenue that are 0.25x to 2.5x that of the Company.
• The peer group companies remain in the peer group each year to maintain a stable and consistent market pay measure, with additions and deletions occurring when required to assure comparability to the Company and to reflect mergers and acquisitions.
• The company's cumulative TSR over the four most recently completed fiscal years to that of the NASDAQ Biotechnology Index (Index) over the same period. We have performed above the Index in all four years.

Related Party Transactions

• Linda Marsh, a board member, is Senior Executive Vice President of AHMC Healthcare, which receives genetic testing services from Fulgent Genetics.
• Prior to its acquisition, Fulgent Pharma LLC was partially owned by Mr. Hsieh, the Chief Executive Officer and Chairperson of the Companys Board of Directors, and the Hsieh Family Dynasty Trust, dated January 27, 2010 (the Hsieh Trust), of which Mr. Hsieh is the grantor.
• Mr. Hsieh is the owner of PTJ Associates Inc. (PTJ). PTJ provides flight services to the Company on an arms-length basis.
• Mr. Hsieh is also on the board of directors and an approximately 20% owner of ANP Technologies, Inc. (ANP), from which the Company purchased COVID-19 antigen rapid test kits and entered into certain drug-related licensing and development service agreements.
• Tiffany Hsieh, the daughter of Mr. Hsieh, works for the Company as an Interaction Designer in the marketing department since December 2020.

Stakeholder Impact

• Shareholders will vote on key proposals that impact the company's governance and executive compensation.
• Employees may be affected by changes in executive compensation and the company's overall financial performance.
• Customers will continue to receive genetic testing services from Fulgent Genetics.
• Suppliers may be impacted by the company's Supplier Code of Conduct and Modern Slavery Statement.
• Creditors' interests are tied to the company's financial stability and ability to meet its obligations.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on May 16, 2024.
• The company will continue to progress its Fulgent Pharma pipeline, aiming for an Investigational New Drug application for FID-022 by the end of 2024.
• The company will continue engaging with its stockholders and to expand such outreach on a consistent annual basis.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Fulgent Genetics, Executive Compensation, Board of Directors, Director Election, Auditor Ratification, Core Revenue, Fulgent Pharma, ESG